Founded in 2002 by experienced pharmaceutical industry executives, CURATIS is a privately owned specialty pharmaceutical company based in Switzerland. CURATIS is focused on the acquisition, development and commercialisation of innovative medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. CURATIS product portfolio included more than 25 medicines in therapy area's such as Oncology, Ultra Rare Diseases, Urology, Neurology, Antidotes and Hospital Products. Our core competencies cover the full range of go-to-market activities, such as - Early Access with Named Patient Programs, - Market Access with Regulatory, Pricing & Reimbursement applications, - Commercialization with Marketing, Sales and Distribution, - State-of-the-art quality and pharmacovigilance expertises, - Stakeholders Management with more than 30 years expertises of dealing with Swiss Health Authorities, Healthcare professionals and patients associations, - Accommodation and implementation of partner-specific requirements (Supply & Distribution Agreement, Master Services Agreement, etc). Partnerships for developing novel medicines To ensure efficient and state-of-the art developments of its pipeline projects, Curatis maintains co-development partnerships with other innovative small and medium-sized biotech/pharmaceutical companies, and also with best-practice contract research and manufacturing organisations. Curatis is looking for co-investors and/or larger pharmaceutical companies for licensing or co-development arrangements for the late stage clinical development of its pipeline projects. Curatis also identifies potential drug candidates for a repurposing development approach in indications with high unmet medical needs via its extensive network within the scientific and medical community, as well as within the biotech/pharmaceutical industry. Curatis invests a significant portion of its revenues and resources in its development activities.